Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William R Wilson

Showing results (61-70 of 125) with videos related to

Pageof 13
Sort By:
Cancer Chemotherapy and Pharmacology|August 5, 2010
A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicityKashyap Patel, Steve S F Choy, Kevin O Hicks, et al.
Biochemical Pharmacology|April 10, 2018
Drug-DNA adducts as biomarkers for metabolic activation of the nitro-aromatic nitrogen mustard prodrug PR-104AAlessia Stornetta, Kai-Cheng Kieren Deng, Sara Danielli, et al.
Chemical Research in Toxicology|April 22, 2003
Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activationNuala A Helsby, S James Wheeler, Frederik B Pruijn, et al.
Journal of Medicinal Chemistry|November 16, 2007
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transportMichael P Hay, Kevin O Hicks, Frederik B Pruijn, et al.
Biochemical Pharmacology|December 21, 2011
Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugsFrancis W Hunter, Jingli Wang, Rita Patel, et al.
Molecular Cancer Therapeutics|June 11, 2009
Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104AYongchuan Gu, Adam V Patterson, Graham J Atwell, et al.
Cancer Research|January 28, 2004
Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317Bronwyn G Siim, Frederik B Pruijn, Joanna R Sturman, et al.
Plos One|June 27, 2013
Zinc finger nuclease mediated knockout of ADP-dependent glucokinase in cancer cell lines: effects on cell survival and mitochondrial oxidative metabolismSusan Richter, Shona Morrison, Tim Connor, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 14, 2007
Influence of mustard group structure on pathways of in vitro metabolism of anticancer N-(2-hydroxyethyl)-3,5-dinitrobenzamide 2-mustard prodrugsNuala A Helsby, Michael A Goldthorpe, Magdalene H Y Tang, et al.
Chemical Research in Toxicology|July 7, 2016
Radical Chemistry and Cytotoxicity of Bioreductive 3-Substituted Quinoxaline Di-N-OxidesRobert F Anderson, Pooja Yadav, Sujata S Shinde, et al.
Pageof 13

Showing results (61-70 of 125) with videos related to

Sort By:
Pageof 13
Cancer Chemotherapy and Pharmacology|August 5, 2010
A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicityKashyap Patel, Steve S F Choy, Kevin O Hicks, et al.
Biochemical Pharmacology|April 10, 2018
Drug-DNA adducts as biomarkers for metabolic activation of the nitro-aromatic nitrogen mustard prodrug PR-104AAlessia Stornetta, Kai-Cheng Kieren Deng, Sara Danielli, et al.
Chemical Research in Toxicology|April 22, 2003
Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activationNuala A Helsby, S James Wheeler, Frederik B Pruijn, et al.
Journal of Medicinal Chemistry|November 16, 2007
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transportMichael P Hay, Kevin O Hicks, Frederik B Pruijn, et al.
Biochemical Pharmacology|December 21, 2011
Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugsFrancis W Hunter, Jingli Wang, Rita Patel, et al.
Molecular Cancer Therapeutics|June 11, 2009
Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104AYongchuan Gu, Adam V Patterson, Graham J Atwell, et al.
Cancer Research|January 28, 2004
Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317Bronwyn G Siim, Frederik B Pruijn, Joanna R Sturman, et al.
Plos One|June 27, 2013
Zinc finger nuclease mediated knockout of ADP-dependent glucokinase in cancer cell lines: effects on cell survival and mitochondrial oxidative metabolismSusan Richter, Shona Morrison, Tim Connor, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 14, 2007
Influence of mustard group structure on pathways of in vitro metabolism of anticancer N-(2-hydroxyethyl)-3,5-dinitrobenzamide 2-mustard prodrugsNuala A Helsby, Michael A Goldthorpe, Magdalene H Y Tang, et al.
Chemical Research in Toxicology|July 7, 2016
Radical Chemistry and Cytotoxicity of Bioreductive 3-Substituted Quinoxaline Di-N-OxidesRobert F Anderson, Pooja Yadav, Sujata S Shinde, et al.
Pageof 13